The 2011 ESRD Prospective Payment System and the Survival of an Endangered Species: The Perspective of a Not-for-Profit Medium-Sized Dialysis Organization

References 

1. Medicare Improvements for Patients and Providers Act of 2008. Medicare, Provisions Relating to Part B, Other Payment and Coverage Improvements. Pub L No. 110-275, §153(a) (2008).
2. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. vol 2. In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;p. 202;http://www.usrds.org/adr.htmAccessed January 4, 2011
3. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. vol 2 In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;p. 220–221http://www.usrds.org/adr.htmAccessed January 4, 2011
4. US Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. vol 2 In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008;p. 172;http://www.usrds.org/adr.htmAccessed January 4, 2011
5. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. vol 2 In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009;p. 330–332http://www.usrds.org/adr.htmAccessed January 4, 2011
6. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. vol 2 In: Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010;p. 360–364http://www.usrds.org/adr.htmAccessed January 4, 2011
7. Hirth RA, Turenne MN, Wheeler JRC, Ma Y, Messana JM. Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?. Med Care. 2010;48(8):726–732
   • CrossRef
8. Lee DKK, Chertow GM, Zenios SA. Reexploring differences among for-profit and nonprofit dialysis providers. Health Serv Res. 2010;45(3):633–646
   • CrossRef
9. Zhang Y, Cotter DJ, Thamer M. The effect of dialysis chains on mortality among patients receiving hemodialysis. Health Serv Res http://www.ncbi.nlm.nih.gov/pubmed/21143480Accessed December 31, 2010
10. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med. 1999;341(22):1653–1660
    • MEDLINE
    • CrossRef
11. de Lissovoy G, Powe NR, Griffiths RI, et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care. 1994;32(2):130–140
    • MEDLINE
    • CrossRef
12. Furth SL, Hwang W, Neu AM, Fivush BA, Powe NR. For-profit versus not-for-profit dialysis care for children with end stage renal disease. Pediatrics. 1999;104(3, pt 1):519–524
    • MEDLINE
    • CrossRef
13. Powe NR, Griffiths RI, Anderson GF, et al. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis. 1993;22(4):557–567
    • Abstract
14. Hirth RA, Chernew ME, Orzol SM. Ownership, competition, and the adoption of new technologies and cost-saving practices in a fixed-price environment. Inquiry. 2000;37(3):282–294
    • MEDLINE